The Ras/Raf/MEK/ERK1/2 pathway plays an essential role in human cancers and its contribution in leukemogenesis has been supported by a high incidence of mutations identified in the RAS gene family, such as NRAS [29–31] and by inappropriate activation of the pathway. This evidence concerns the gene MAPK3 and cancer.